(KPL/Yonhap) Samsung Biologics Co. said Tuesday it has signed a deal worth US$1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm.
The deal will last until the end of 2037, the company said in a regulatory filing. Other …